1-thia-4-aza-bicyclo (3.2.0) Heptane Ring Containing (including Dehydrogenated) (e.g., Penicillins, Etc.) Patents (Class 514/192)
  • Patent number: 10519161
    Abstract: The present invention includes compositions, methods of making and using novel carbapenem compounds including active agents, compounds, antibacterial agents, pharmaceutically acceptable salts of C1?-C1? di-substituted carbapenem compounds, C5? substituted carbapenem compounds, C6?-C6? di-substituted carbapenem compounds and combinations thereof.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: December 31, 2019
    Assignee: Southern Methodist University
    Inventor: John D. Buynak
  • Patent number: 10420841
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: September 24, 2019
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandron Donadelli, Dario Resemini
  • Patent number: 10376496
    Abstract: Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: August 13, 2019
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Gopal Krishna, Gurudatt Chandorkar, Elham Hershberger, Benjamin Miller, Alan Xiao
  • Patent number: 10350177
    Abstract: Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Francisella tularensis. The present invention provides compounds, methods and compositions effective to treat microbial/bacterial infections, and, especially, infections arising from bacteria which have developed resistance to conventional antibiotics.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: July 16, 2019
    Assignee: University of South Florida
    Inventors: Edward Turos, Praveen Ramaraju
  • Patent number: 10166253
    Abstract: The present invention provides a positively charged co-polymer for use as an antimicrobial agent, wherein said positively charged co-polymer is composed of amino acids and/or derivatives thereof and wherein at least 75 molar percent of said amino acids are selected from the group consisting of alanine, lysine, glutamate, arginine and tyrosine and/or derivatives thereof. The present invention also provides methods for treating, preventing or ameliorating a microbial infection comprising administration of positively charged random co-polymers as well as a pharmaceutical composition comprising said co-polymer. The invention further provides a kit of parts comprising the positively charged random co-polymer.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: January 1, 2019
    Assignees: Region Midtjylland, Aarhus Universitet
    Inventors: Thomas Vorup Jensen, Stig Hill Christiansen, Jørgen Eskild Petersen
  • Patent number: 9925196
    Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Patent number: 9545381
    Abstract: The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (Karl-Fischer) of not more than 4.2%.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: January 17, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Albert Barta
  • Patent number: 9346799
    Abstract: A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a ?-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another ?-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: May 24, 2016
    Assignee: Basilea Pharmaceuticals AG
    Inventors: Eric Desarbre, Bérangère Gaucher, Malcom G. P. Page, Patrick Roussel
  • Patent number: 9115079
    Abstract: An objective of the present invention is to provide a novel NDM (New Delhi metallo-?-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of ?-lactam antibiotics that have been inactivated as a result of decomposition by NDM.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: August 25, 2015
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Akihiro Morinaka, Kazunori Maebashi, Takashi Ida, Muneo Hikida, Mototsugu Yamada, Takao Abe
  • Patent number: 9034380
    Abstract: Materials and Methods are disclosed for producing nanoparticles linked to antibacterial ligands, including antibiotics and/or molecules which bind to bacterial markers, and for the use of the nanoparticles for the treatment of conditions treatable by the antibiotic ligands.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: May 19, 2015
    Assignee: Midatech Ltd.
    Inventors: Thomas William Rademacher, Godfrey Bradman, Soledad Penades Ullate, Rafael Ojeda Martinez De Castilla
  • Publication number: 20150094293
    Abstract: Novel solid forms of ceftolozane are described, as well as methods for the preparation and use of these solid forms.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 2, 2015
    Applicant: CALIXA THERAPEUTICS, INC.
    Inventors: Valdas Jurkauskas, Nicole Miller Damour, Lisa Duong, You Seok Hwang, Kristos Adrian Moshos, Sanjay Mudur, Asli Ovat, Joseph Terracciano, Jason Woertink
  • Publication number: 20150079155
    Abstract: This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, T-lymphocytes, B-lymphocytes and/or NK cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 19, 2015
    Inventors: Simon Skjøde Jensen, Thomas Lars Andresen, Jonas Rosager Henriksen, Pia Thermann Johansen
  • Publication number: 20150080360
    Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Calixa Therapeutics, Inc.
    Inventors: Gurudatt A. Chandorkar, Jennifer A. Huntington, Tara Parsons, Obiamiwe C. Umeh
  • Publication number: 20150072968
    Abstract: Disclosed is a method of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
    Type: Application
    Filed: May 23, 2014
    Publication date: March 12, 2015
    Applicant: Calixa Therapeutics, Inc.
    Inventors: Gopal Krishna, Gurudatt Chandorkar, Elham Hershberger, Benjamin Miller, Alan Xiao
  • Publication number: 20150072957
    Abstract: This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Applicant: Calixa Therapeutics, Inc.
    Inventors: Jan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20150072961
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Chongxi YU, Lina XU
  • Publication number: 20150065416
    Abstract: There is provided inter alia a method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of: (a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide; and (b) an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampifin and sulbactam.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Coralie Mouzé, Vincent Gerusz, Alexis Denis
  • Patent number: 8968753
    Abstract: Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: March 3, 2015
    Assignee: Calixa Therapeutics, Inc.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Publication number: 20150045336
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of making those compositions, and related methods and uses of these compositions.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Publication number: 20150031658
    Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
    Type: Application
    Filed: October 15, 2014
    Publication date: January 29, 2015
    Inventors: Patrick C. Seed, Carlos C. Goller, Apurba Dutta, Brooks Maki, Frank Schoenen, James Noah, Lucile White
  • Patent number: 8937062
    Abstract: Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: January 20, 2015
    Assignee: Bausch & Lomb Incorporated
    Inventors: Praveen Tyle, Pramod Kumar Gupta, Susan E. Norton, Lynne Brunner, Joseph Blondeau
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140371194
    Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
    Type: Application
    Filed: June 16, 2014
    Publication date: December 18, 2014
    Inventors: Patrick C. Seed, Carlos C. Goller, Apurba Dutta, Brooks Maki, Frank Schoenen, James Noah, Lucile White
  • Publication number: 20140348936
    Abstract: Gastroretentive controlled release vehicles may, in some embodiments, (1) comprise a polymeric matrix and agents for the treatment, prevention, and/or mitigation of a disease and/or side effect thereof and (2) have both gastroretentive properties and controlled release properties. Preferrably, the polymeric matrix may comprise ethylene copolymers, ethyl celluloses, and/or thermoplastic polyurethanes that may optionally be partially crosslinked.
    Type: Application
    Filed: December 17, 2012
    Publication date: November 27, 2014
    Inventors: Jose Reyes, Kenneth Anderson, Dale Zevotek, Nathan Reuter, J. Gregory Little, Jeffrey Haley, Vassilios Galiatsatos
  • Publication number: 20140329793
    Abstract: The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.
    Type: Application
    Filed: October 19, 2012
    Publication date: November 6, 2014
    Applicant: SEACHAID PHARMACEUTICALS, INC.
    Inventors: Balasingam Radhakrishnan, Anuradha Vaidya, Navdeep Balkrishna Malkar, Karen Polowy, Kenneth Duke James, JR.
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Publication number: 20140314827
    Abstract: Described herein are compositions comprising at least one buffering agent, at least one chelating agent and at least one antimicrobial agent, which can be used for treating and/or preventing diseases or disorders in a variety of animals. In certain embodiments, in particular, the compositions can be used for treating and/or preventing ophthalmic and oral cavity diseases or disorders in dogs and cats and oropharyngeal and/or guttural pouch diseases or disorders in equines. In certain embodiments, the compositions can also be used for treating ophthalmic or oral cavity diseases or disorders in humans.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Inventor: Steven A. Melman
  • Publication number: 20140309205
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 16, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour, Yanmei Lan, Jonathan Cam Ly, Jianxun Zhou
  • Publication number: 20140303136
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 9, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour, Yanmei Lan, Jonathan Cam Ly, Jianxun Zhou
  • Publication number: 20140303101
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140274993
    Abstract: Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140274991
    Abstract: Pharmaceutical compositions can include ceftolozane and an amount of sodium chloride effective to provide improved ceftolozane stability.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Nicole Miller Damour, Joseph Terracciano
  • Publication number: 20140274925
    Abstract: Disclosed herein are compositions and methods for diagnosing, treating, and monitoring Lyme disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Chenggang Jin, Gottfried H. Kellermann
  • Publication number: 20140274989
    Abstract: This disclosure relates to the manufacture of pharmaceutical compositions comprising an antibiotic compound and a beta-lactamase inhibitor compound when both compounds have a chemical structure that includes a beta-lactam ring, as well as resulting pharmaceutical compositions.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140274992
    Abstract: Pharmaceutical formulations can include ceftolozane and an alkalizing agent such as L-arginine.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Nicole Miller Damour, Jacqueline Marie Walsh, Joseph Terracciano
  • Publication number: 20140274996
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of making those compositions, and related methods and uses of these compositions.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Nicole Miller Damour, Joseph Terracciano
  • Publication number: 20140274998
    Abstract: Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 18, 2014
    Applicant: Cubist Pharmaceuticals, Inc.
    Inventors: Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140274997
    Abstract: Pharmaceutical compositions including a cephalosporin disclosed herein as having the structure of formula (III).
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jianxun Zhou, Nicole Miller Damour, Yanmei Lan, Jonathan Cam Ly, Joseph Terracciano
  • Publication number: 20140274995
    Abstract: Parenteral pharmaceutical compositions including ceftolozane and tazobactam can be formulated to provide desired levels of osmolality, pH and ceftolozane stability.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Jianxun Zhou, Nicole Miller Damour, John Fred Mohr, Joseph Terracciano, Jacqueline Marie Walsh
  • Publication number: 20140274994
    Abstract: Pharmaceutical compositions can include an amount of a ceftolozane and a stabilizing agent in a formulation for parenteral administration.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventor: Nicole Miller Damour
  • Publication number: 20140262868
    Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140274990
    Abstract: Pharmaceutical compositions can include an amount of sodium chloride effective to stabilize ceftolozane in a lyophilized formulation.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140243302
    Abstract: Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.
    Type: Application
    Filed: June 26, 2012
    Publication date: August 28, 2014
    Applicants: MERCK SHARP & DOHME CORPORATION, KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Yasumichi Fukuda, David E. Kaelin, JR., Sheo B. Singh
  • Publication number: 20140228312
    Abstract: The present invention relates to a composition comprising: an antibiotic selected from the group consisting of an aminoglycoside antibiotic, a beta-lactam antibiotic, an ansamycin antibiotic, a macrolide antibiotic, a sulfonamide antibiotic, a quinolone antibiotic, an oxazolidinone antibiotic, a glycopeptide antibiotic, and a mixture thereof; and a fatty acid represented by formula (I), a stereoisomer, a salt or an ester thereof, wherein R1 is a substituted or unsubstituted aliphatic group.
    Type: Application
    Filed: October 1, 2012
    Publication date: August 14, 2014
    Inventors: Lianhui Zhang, Yinyue Deng
  • Publication number: 20140228337
    Abstract: This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 14, 2014
    Applicant: CUBIST PHARMACEUTICALS, INC.
    Inventors: Jan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140221330
    Abstract: An objective of the present invention is to provide a novel NDM (New Delhi metallo-?-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of ?-lactam antibiotics that have been inactivated as a result of decomposition by NDM.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 7, 2014
    Inventors: Akihiro Morinaka, Kazunori Maebashi, Takashi Ida, Muneo Hikida, Mototsugu Yamada, Takao Abe
  • Publication number: 20140213566
    Abstract: Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically acceptable salt thereof, and (c) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.
    Type: Application
    Filed: October 4, 2011
    Publication date: July 31, 2014
    Applicant: Wockhardt Limited
    Inventors: Sachin Subhash Bhagwat, Mahesh Vithalbhai Patel
  • Publication number: 20140213567
    Abstract: This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Inventors: Jan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140206659
    Abstract: This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions.
    Type: Application
    Filed: April 11, 2014
    Publication date: July 24, 2014
    Inventors: Jan-Ji Lai, Jian-Qiao Gu, Pradip M. Pathare, Valdas Jurkauskas, Joseph Terracciano, Nicole Miller Damour
  • Publication number: 20140193517
    Abstract: Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second pharmaceutical intended for treatment of said at least one disease or disorder; determining an association strength between the drug-side effect (SE) association and the disease-side effect (SE) association; selecting said at least one disease or disorder as a new therapeutic indication for said at least one first pharmaceutical if said at least one first pharmaceutical induces at least one side effect which is the same as at least one side effect induced by at least one second pharmaceutical intended for treatment of said at least one disease or disorder.
    Type: Application
    Filed: August 17, 2012
    Publication date: July 10, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Pankaj Agarwal, Lun Yang